Skip to main content

Emergent BioSolutions awarded contract from HHS to support smallpox preparedness

Submitted by lsekela on June 10, 2019 - 09:23 AM

The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.

Content Source:

Homeland Preparedness News

Content Author:

Dave Kovaleski